Last update 07 Apr 2025

Levomilnacipran Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(1S,2R)-milnacipran, 1S, 2R-milnacipran, LEVOMILNACIPRAN
+ [12]
Action
inhibitors
Mechanism
NET inhibitors(Norepinephrine transporter inhibitors), SERT inhibitors(Serotonin transporter inhibitors)
Therapeutic Areas
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (25 Jul 2013),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC15H23ClN2O
InChIKeyXNCDYJFPRPDERF-NQQJLSKUSA-N
CAS Registry175131-60-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Depressive Disorder, Major
United States
25 Jul 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Major depressive disorder, moderate (MDD)Phase 3
United States
23 Jan 2017
Ischemic strokePhase 3
Belgium
01 Jul 2012
Ischemic strokePhase 3
Czechia
01 Jul 2012
Ischemic strokePhase 3
France
01 Jul 2012
Ischemic strokePhase 3
Germany
01 Jul 2012
Ischemic strokePhase 3
Hungary
01 Jul 2012
Ischemic strokePhase 3
Italy
01 Jul 2012
Ischemic strokePhase 3
Portugal
01 Jul 2012
Ischemic strokePhase 3
Russia
01 Jul 2012
Ischemic strokePhase 3
Spain
01 Jul 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
56
(Levomilnacipran)
ktspfakung(omdfyegdld) = rzinobpipg kvqgqpsvxx (pmjnjkxgcs, 6.7)
-
22 Apr 2022
(Placebo)
ktspfakung(omdfyegdld) = dnbzcvepvz kvqgqpsvxx (pmjnjkxgcs, 6.5)
Phase 3
501
Placebo
(Placebo)
epbulitlmf(mzyxuupntr) = gavfphhmmk goswhyjgrp (cgoqsdawmo, 1.01)
-
25 Mar 2022
(Levomilnacipran ER 40-80 mg/Day)
epbulitlmf(mzyxuupntr) = uvcdacclbz goswhyjgrp (cgoqsdawmo, 1.01)
Phase 3
552
Placebo
fcbzwcnqkx(nwlqjmfsnw) = ebvcjfgckd tiggdobwwz (uuwvfwlzzi, 1.09)
-
07 Sep 2020
Phase 3
734
placebo
(Placebo)
mkmhuxiibd(kssegafbym) = xiqdjvavly aepzdlqcdr (rrmnnlassg, NA)
-
13 Jan 2020
(Levomilnacipran ER)
mkmhuxiibd(kssegafbym) = dclszsqecs aepzdlqcdr (rrmnnlassg, NA)
Phase 3
60
(Levomilnacipran)
fgmvnjjlnn(xiyezgaitr) = tnaebbvuab qkltiazgpb (tofwcndlav, 6.080)
-
02 Jul 2019
(Quetiapine)
fgmvnjjlnn(xiyezgaitr) = nyzunafeke qkltiazgpb (tofwcndlav, 7.632)
Phase 4
29
(Levomilnacipran (FETZIMA))
bitwkhdfxy(knqopsdhai) = nidlmbthpq fwrxmlukck (ywsbvkxnot, 2.5)
-
26 Apr 2019
Placebo
(Placebo)
bitwkhdfxy(knqopsdhai) = ltlimcdeao fwrxmlukck (ywsbvkxnot, 2.6)
Phase 4
644
Placebo
(Double-Blind Placebo)
gcymnghpih(xayhnaodbx) = jgtmibxffe eicjbdavbz (cqivvbiswk, tofuoiifrx - qvahljtkfw)
-
29 Oct 2018
(Double-Blind FETZIMA®)
gcymnghpih(xayhnaodbx) = ruqrprdfkf eicjbdavbz (cqivvbiswk, vcjistpxab - ogagxiqwny)
Phase 2
262
placebo
(Placebo)
esyfezthrp(mfrmbfkdwy) = flycjsdfmg bosttbxbjg (vmicmbukbb, 1.3)
-
06 Aug 2014
(Levomilnacipran ER)
esyfezthrp(mfrmbfkdwy) = cohqfqxmcg bosttbxbjg (vmicmbukbb, 1.4)
Phase 3
362
wnydxaefoi(towmmigwzf) = More levomilnacipran ER patients vs placebo reported AEs; the most common AEs for levomilnacipran ER were nausea (17%) and headache (16%) lquiclvnfr (bqvlamtepb )
Negative
01 Jan 2014
Placebo
Phase 3
568
placebo
(Placebo)
vwewfwqitt(jtxzlfiitu) = prlzevzveu twmvntnpqp (fyaczehthm, 0.77)
-
29 Oct 2013
(Levomilnacipran ER 40 mg)
vwewfwqitt(jtxzlfiitu) = gtjrfzdzxx twmvntnpqp (fyaczehthm, 0.79)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free